Summary The cell kinetics of 82 squamous cell carcinomas of the head and neck were studied by in vivo administration of the thymidine analogue, bromodeoxyuridine (BrdUrd). Ploidy, BrdUrd labelling index (LI), duration of S-phase (Ts), potential doubling time (Tpot) and S-phase (Steel, 1977; Meyer, 1982) . Cell kinetic studies in man, until recently, have been limited to in vitro investigations because of the ethical constraints of administering radioactive DNA precursors to patients. Tritiated thymidine labelling of freshly excised tissue followed by autoradiography has been widely used (Gentili et al., 1981; Brandt & Olsson, 1987; Courdi et al., 1989; Meyer & Bauer, 1975) . The development of flow cytometric methods for measuring DNA content, particularly in paraffin embedded archival material, has resulted in DNA ploidy and S-phase fraction analysis being performed for many tumour types (Cornelisse et al., 1987; Armitage, 1985; Feichter et al., 1987 
Summary The cell kinetics of 82 squamous cell carcinomas of the head and neck were studied by in vivo administration of the thymidine analogue, bromodeoxyuridine (BrdUrd) . Ploidy, BrdUrd labelling index (LI), duration of S-phase (Ts), potential doubling time (Tpot) and S-phase The kinetics of tumour growth may be an important factor influencing tumour aggression and the course of malignant disease. Kinetic parameters may therefore be of value in assessing prognosis and the response of tumours to cytostatic treatment (Steel, 1977; Meyer, 1982) . Cell kinetic studies in man, until recently, have been limited to in vitro investigations because of the ethical constraints of administering radioactive DNA precursors to patients. Tritiated thymidine labelling of freshly excised tissue followed by autoradiography has been widely used (Gentili et al., 1981; Brandt & Olsson, 1987; Courdi et al., 1989; Meyer & Bauer, 1975) . The development of flow cytometric methods for measuring DNA content, particularly in paraffin embedded archival material, has resulted in DNA ploidy and S-phase fraction analysis being performed for many tumour types (Cornelisse et al., 1987; Armitage, 1985; Feichter et al., 1987 (Fowler, 1985; Thames et al., 1983; Begg et al., 1990) . The clinical application of cell kinetic information requires a technique which generates results rapidly within a day or two of biopsy. The use of tritiated thymidine and autoradiography is therefore unsuitable.
The development of a monoclonal antibody to bromodeoxyuridine (BrdUrd) (Gratzner, 1982) , a thymidine analogue which can be safely administered to patients, together with a technique that simultaneously measures incorporated bromodeoxyuridine (BrdUrd) and DNA content by flow cytometry (Dolbeare et al., 1983) has facilitated the study of human tumour cell kinetics. Begg et al. (1985) BrdUrd/DNA staining The nuclear preparation was denatured by 2 M HCl at room temperature for 30 min. 0.1 M Borax pH 8.5 was used to neutralise the acid. The samples were then washed twice, first with PBS and then with PBS containing 1% bovine serum albumin and 0.1% Tween 20 (PBT). The nuclear suspension was then incubated with 100 gl of mouse anti-BrdUrd (Dako Ltd, High Wycombe) at a dilution of 1/30 for 1 h at room temperature, washed twice in PBT, followed by incubation with 100 lil of goat anti mouse-FITC conjugated antibody (Sigma Chemical Co, Poole) for 30 min at room temperature at a dilution of 1/40. After washing thoroughly in PBT, then PBS, the samples were stained with propidium iodide at a concentration of 10 ig ml' for 30 min at room temperature or at 4°C overnight.
Flow cytometric analysis Flow cytometric analysis (FCM) of the samples was performed using a Coulter Epics Profile II flow cytometer fitted with a 15 mW air cooled argon ion laser emitting at 488 nm. Green and red fluorescent emissions were collected through a 525 nm band pass and 610 nm long pass filter respectively. Data acquisition was in list mode and between 10,000-100,000 nuclei were recorded. Aggregates of whole nuclei and nuclear debris were excluded from the data list by gating on the DNA area vs peak signal.
Calculation of cell cycle parameters A typical flow cytometric output for an aneuploid tumour is illustrated in Figure 1 .
The duration of S-phase (Ts) and the potential doubling time (Tpot) was calculated by the method developed by Begg et al. (1985) . The relative movement, a measure of how far labelled cells have travelled through the S-phase in the labelling time, and the BrdUrd labelling index (LI) i.e. the number of BrdUrd labelled cells expressed as a percentage of the total cell population, were both calculated by on-screen analysis using the Epics Profile II software. When calculating the BrdUrd LI the number of labelled cells in Gl was halved to correct for the division that these cells had undergone since being labelled. For aneuploid tumours the combined LI of aneuploid and diploid cells (total LI) and that of the aneuploid component only was calculated. When calculating the total LI cells that had moved into GI were not halved as before. A total LI was also calculated in this way for diploid tumours so that aneuploid and diploid tumours could be compared. This results in the small difference between LI and total LI for diploid tumours seen in Table II . The relative movement and the tumour LI were used to calculate values of Ts and Tpot using equations (1) and (2) below. All Tpot calculations for aneuploid tumours were made using the LI of the aneuploid component. 
LI where t is the labelling time and A is a correction factor for the non-linear age distribution of cells through the cell cycle. It was assumed to be 0.8 (Steel, 1977) . Calculation of lablling index and relative movement was often difficult for aneuploid tumours where there was overlap with a diploid population. In these cases diploid cells with labelled late S-phase and G2M nuclei overlapped with aneuploid cells labelled in the GI and S-phase. Consequently the labelling index of the aneuploid component was artificially high and the relative movement was biased towards the aneuploid GI causing the Ts to be longer than its 'true' value. Where there was a significant proportion of diploid cells in aneuploid tumour samples (over 80% of cases), labelled diploid cells with late S and G2M DNA content were excluded from the analysis. This was achieved by delineating the area between the end of the GI aneuploid peak and the end of the diploid G2M peak and excluding the labelled cells in this area. Thus they made no contribution to the LI and relative movement. In aneuploid tumours where there was low labelling associated with the diploid component this procedure made little difference to the LI and the Ts calculated, but in those with high labelling the LI and Ts could be significantly reduced. The procedure was made easier when there was a clear demarcation between the labelled diploid and aneuploid cohorts of cells. S-phase fractions were measured from DNA histograms generated for BrdUrd/DNA analysis using a simple 'rectangular fit' model provided by Cytologic software, Coulter Electronics. These were corrected for background by exponential subtraction. (Bland & Altman, 1986; Murray & Miller, 1990 SPF analysis S-phase analysis was performed successfully on 69 tumours, 13 histograms of aneuploid tumours being unsuitable for analysis. The median SPF for all tumours was 11.5%. The SPF of aneuploid tumours was significantly higher than that of diploid tumours (U = 579, P <0.01), (Table II) . The correlation between the BrdUrd labelling index and S-phase fraction was poor (r = 0.67) considering they are supposedly measuring the same parameter. SPF was on average 1.8 times greater than the BrdUrd labelling index.
Discussion
The measurement of cell kinetic parameters in vivo in humans has only recently become possible using the thymidine analogue, bromodeoxyuridine (BrdUrd). The method developed by Begg et al. (1985) (Friedlander et al., 1984; Volm et al., 1985) including some head and neck tumours (Holm, 1982; Franzen et al., 1986) 11.5 7.9 14.8 P<0.01 (2.6-30.0) (2.6-14.7) (7.6-30.0) in breast cancer where high TLI correlates with reduced survival (Meyer & Hixon, 1979; Gentili et al., 1981) and may also predict tumour radio and chemosensitivity (Silvestrini et al., 1984) . The relationship between TLI and prognosis is not so well established in head and neck cancer where unlike in breast cancer the median TLI fails to divide patients into two groups with significantly different outlook (Courdi et al., 1988) . However Chauvel et al. (1989) showed in a series of head and neck tumours, that choosing a value above the median TLI as a cut-off point identified a small group of patients with significantly reduced survival when the median failed to do so.
The results obtained in this study are similar to the limited number of in vivo cell kinetic studies published to date. The median labelling index of 8.0% compares well with the 7.8% observed by Wilson et al. (1988) after in vivo BrdUrd labelling of nine head and neck tumours. Other in vivo studies employing tritiated thymidine have quoted slightly higher values ranging from 11.7-28.6% (Bresciani et al., 1974; Sakuma, 1980) but the sample sizes in these studies were very small. Much larger cohorts of patients have been studied using in vitro thymidine labelling. Three such studies (Chauvaudra et al., 1979; Silvestrini et al., 1984; reported a median value of 11% for head and neck tumours. Agreement between labelling indices determined from in vitro and in vivo labelling experiments is difficult to assess, but indirect evidence from simple comparisons of separate studies show the range of values are comparable. Studies specifically addressing the problem have reported good correlation between values on the whole, but with some instances of underestimation of the Li in vitro (Denekamp & Kallman, 1973; Chauvaudra et al., 1979) . Whether or not the in vitro LI truly reflects the actual in vivo labelling index, its value as a prognostic marker, at least in some tumours, is well established and still continues to be widely used.
The median Ts measured in this study of 11.5 h is similar to that previously reported for oral cancers (Sakuma, 1980; Silvestrini et al., 1984) . Recent in vivo studies have reported short mean Ts values of between 10-12 h and short median potential doubling times of 4-5 days which agree well with our values (Wilson et al., 1988; Begg et al., 1990) .
It has been suggested that fast growing tumours may be more responsive to cytostatic therapy presumably because a large proportion of cells are in cycle. Feichter et al. (1987) observed that although the majority of tumours which failed to respond to therapy had a low SPF, there was a small group of non-responders with high SPF. One possible reason for this is that the cell regeneration rate is in excess of cell destruction, significant cell repopulation taking place in between treatment periods. For this reason conventional radiotherapy regimes may be unsuitable for fast growing tumours. An accelerated course of treatment where the treatment time is shortened from 4 weeks to 3 weeks or less may be more suitable in these cases (Thames et al., 1983; Fowler, 1985) . Such aggressive treatment presents a greater risk to the patient and may necessitate longer periods of hospitalisation. The measurement of cell cycle parameters, in particular the potential doubling time, for individual patients would identify those that may benefit from accelerated radiotherapy. Similarly, chemotherapy for patients with advanced head and neck cancer could be limited to those patients who are most likely to respond, sparing potential non-responders form debilitating chemotherapy regimes.
It has been proposed that tumours with a potential doubling time of 5 days or less may benefit from accelerated fractionation (Thames et al., 1983; Fowler, 1985) . Results for accelerated radiotherapy have been promising, particularly when combined with hyperfractionation (multiple fractions per day), and given over a continuous 12 day period (Continuous hyperfractionated accelerated radiotherapy -CHART) (Saunders & Dische, 1986) . A multi-centre randomised trial has recently begun to test the efficacy of CHART compared with conventional treatment. It is hoped that cell kinetic data will also be available in those centres currently undertaking BrdUrd studies. Preliminary data from a similar accelerated radiotherapy trial for head and neck cancer which begun in 1986 has shown that there was improved local control of fast growing tumours as measured by in vivo iododeoxyuridine (IUdR) labelling when given accelerated treatment compared to conventional treatment (Begg et al., 1990) . Using the suggested cut-off point of 5 days to discriminate between quickly and slowly growing tumours, 28 tumours out of 82 in our study qualified as candidates for accelerated treatment. Twenty-five of these tumours were aneuploid, three were diploid. The potential doubling time of aneuploid tumours was significantly less than that of diploid tumours which may explain the observation that aneuploid tumours are often more responsive to therapy (Franzen et al., 1986; Barlogie et al., 1987; Guo et al., 1989) . We have previously reported that in advanced unresectable squamous carcinoma of the head and neck there was a significant prolongation of survival in patients with aneuploid tumours compared with patients with diploid tumours when treated with cisplatin (Cooke et al., 1990) . However a recent meta analysis of published data from six separate head and neck ploidy studies representing 1047 cases has cast doubt on the prognostic value of tumour DNA content in head and neck tumours other than in oral cancer (Stell, 1991) .
As well as its potential use as a indicator of radio-and chemosensitivity the potential doubling time may be useful in assessing prognosis. Evidence suggests that tumours with short potential doubling times have shorter relapse free intervals and vice versa (Trott & Kummermehr, 1985) . One might expect Tpot data to have greater predictive power with regard to prognosis and response to therapy than labelling indices since they represent a dynamic measure conveying more accurate information about tumour growth potential. However the superiority of Tpot over labelling index and other static measures of proliferation like SPF and ploidy remains to be proven. The discrepancy between BrdUrd LI and SPF seen in this study is consistent with other workers observations and occurs due to the presence of cells with S-phase DNA content that have failed to take up the DNA label (Allison et al., 1985; Wilson et al., 1985) . These cells may have simply arrested in S-phase or are synthesising DNA at such a slow rate that the short exposure time of the DNA label is insufficient to allow any detectable incorporation to take place.
In this study cell kinetic measurements obtained from 50pm sections were similar to those obtained from small 
